Flutamide Therapy for Advanced Prostatic Cancer: a Phase II Study
- 1 April 1985
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 57 (2) , 172-174
- https://doi.org/10.1111/j.1464-410x.1985.tb06415.x
Abstract
A non-steroidal antiandrogen (flutamide) was used to treat 17 patients with advanced prostatic cancer. Twelve of 14 patients who had already failed to respond to conventional hormone therapy were dead within 12 mo. of starting flutamide therapy and there was a high incidence of side effects. Of 3 patients who had not received prior hormone therapy, 2 showed an early partial response and 1 showed no evidence of response to therapy.This publication has 6 references indexed in Scilit:
- Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial*British Journal of Urology, 1980
- Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancerUrology, 1976
- Sch 13521 In The Treatment Of Advanced Carcinoma Of The ProstateJournal of Urology, 1974
- On the Mechanism of the Anti-androgenic Action ofFlutamide (α-α-α-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide)in the RatEndocrinology, 1974
- A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4'–Nitro–3'–Trifluoromethylisobutyranilide)1Endocrinology, 1972
- Cortisone Treatment in Advanced Carcinoma of the ProstateJournal of Urology, 1954